Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ampelopsis grossedentata total flavonoids is a botanical drug extract derived from the leaves and stems of *Ampelopsis grossedentata*, commonly known as vine tea or Moyao tea. Developed by Shaanxi Bailu Pharmaceutical, it is primarily indicated for the treatment of acute pharyngitis. The extract is highly enriched in flavonoids, with dihydromyricetin (DHM) serving as the principal active constituent, often comprising over 90% of the total flavonoid content. Its therapeutic mechanism involves potent anti-inflammatory, antibacterial, and antioxidant activities. It works by inhibiting the production of pro-inflammatory cytokines and mediators, such as TNF-alpha, IL-6, and COX-2, thereby reducing throat pain, swelling, and congestion. It was approved in China as a Class 5 new Chinese medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ampelopsis grossedentata total flavonoids.